Zacks Research Raises Earnings Estimates for Zimmer Biomet

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Investment analysts at Zacks Research increased their Q4 2024 EPS estimates for shares of Zimmer Biomet in a report issued on Wednesday, November 20th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will earn $2.29 per share for the quarter, up from their previous forecast of $2.26. The consensus estimate for Zimmer Biomet’s current full-year earnings is $7.99 per share. Zacks Research also issued estimates for Zimmer Biomet’s Q2 2025 earnings at $2.13 EPS and Q1 2026 earnings at $2.28 EPS.

Several other equities analysts have also weighed in on the company. Canaccord Genuity Group reduced their price objective on Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating on the stock in a research note on Tuesday, September 10th. TD Cowen decreased their price objective on shares of Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating for the company in a research note on Friday, September 6th. Raymond James dropped their price objective on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a research report on Monday, October 14th. Royal Bank of Canada lifted their target price on shares of Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a report on Monday, November 4th. Finally, Truist Financial increased their price target on Zimmer Biomet from $112.00 to $117.00 and gave the company a “hold” rating in a report on Friday, November 1st. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $123.22.

Zimmer Biomet Price Performance

Shares of Zimmer Biomet stock opened at $110.96 on Monday. The business’s fifty day moving average price is $106.86 and its 200 day moving average price is $109.54. Zimmer Biomet has a twelve month low of $101.47 and a twelve month high of $133.90. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $22.09 billion, a P/E ratio of 21.10, a PEG ratio of 2.03 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The company had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. During the same quarter last year, the firm posted $1.65 earnings per share. Zimmer Biomet’s revenue was up 4.1% on a year-over-year basis.

Institutional Investors Weigh In On Zimmer Biomet

Several hedge funds and other institutional investors have recently modified their holdings of ZBH. Dunhill Financial LLC lifted its position in shares of Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 218 shares during the last quarter. Ashton Thomas Securities LLC bought a new position in Zimmer Biomet during the 3rd quarter worth approximately $28,000. Bangor Savings Bank acquired a new position in shares of Zimmer Biomet in the 3rd quarter worth approximately $31,000. Family Firm Inc. bought a new stake in shares of Zimmer Biomet in the 2nd quarter valued at approximately $33,000. Finally, Brooklyn Investment Group acquired a new stake in shares of Zimmer Biomet during the 3rd quarter valued at approximately $35,000. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were paid a $0.24 dividend. The ex-dividend date was Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.87%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 18.25%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.